Antigens of the ABO system and clinical manifestations of Covid-19 in a health area of the Bayamo municipality
Keywords:
COVID-19, SARS-CoV-2, Grupos sanguíneos ABO, Antígenos A, B y O, Síntomas/signos.Abstract
Introduction: A plethora of symptoms/signs have been described that clearly indicate that COVID-19 is a complex disease, and a growing number of reports have suggested that ABO blood groups are related to the risk of developing the disease.
Objective: to identify if there is a relationship between the blood phenotypes of the ABO system and the clinical manifestations of Covid-19 in a health area in the Bayamo municipality.
Method: a retrospective descriptive study was carried out, which included 123 confirmed COVID-19 patients with epidemiological discharge. Blood group was determined according to the ABO system. The subjects were classified according to the number of symptoms/signs, the predominance of respiratory symptoms/signs or not. The association between the blood groups of the ABO system, the carriers of the different antigens in comparison with those of those without the antigen and the groups by number of symptoms and signs, and according to predominance or not of respiratory symptoms/signs was analyzed.
Results: a significant association was found between the blood group of the patients and the groups according to the number of symptoms/signs presented, as well as between carriers of B and non-B antigens and the groups according to the number of symptoms/signs presented and the predominance of respiratory symptoms or not, in all cases with a higher frequency of patients with phenotype A.
Conclusions: it is concluded that in this study the blood group of patients positive for Covid-19 was related to the number of symptoms/signs presented, with a predominance of the frequency of carriers of antigen A over the others.
Keywords: COVID-19; SARS-CoV-2; ABO blood groups; Antigens A, B and O; Symptoms / signs.
Downloads
References
1. Pérez Abreu MR, Gómez Tejeda JJ, Dieguez Guach RA. Características clínico-epidemiológicas de la COVID-19. Rev haban cienc méd. 2020; 19(2): e3254.
2. Roblejo Balbuena H, Benítez Cordero Y, Álvarez Gavilán Y, Bravo Ramírez M, Pereira Roche N, García Gómez D, et. al. Características clínico-epidemiológicas de pacientes cubanos residentes en La Habana afectados por la COVID-19. Rev Cubana Investig Bio. 2021; 40(4): e1566.
3. Dashboard Cuba: Covid19cubadata. [Internet]. 2021 [citado 27/08/2021]. Disponible en: https://covid19cubadata.github.io/#cuba
4. Romo Domínguez KJ, Saucedo Rodríguez EG, Hinojosa Maya S, Mercado Rodríguez JY, Uc Rosaldo JE, Ochoa García E, et al. Manifestaciones clínicas de la COVID-19. Rev Latin Infect Pediatr. 2020; 33(s1): s10-s32.
5. Fernández Botrán R. Asociación del grupo sanguíneo ABO con susceptibilidad a COVID-19. Ciencia, Tecnología y Salud. 2020; 7(3): 325 - 32.
6. Peña García Y, Suárez Padilla A, Arruebarrena Blanco NM. Caracterización de casos positivos y sospechosos de COVID-19 con comorbilidades. Revista Finlay [Internet]. 2020 ]; 10(3):314-9.
7. Yujia Zhang, Rachael Garner, Sana Salehi, Marianna La Rocca, Dominique Duncan. Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies. Annals of Hematology. 2021; 100: 1123_32.
8. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. Viruses 2021; 13(2): 160-80.
9. Fan Q, Zhang W, Li B, Li DJ, Zhang J, Zhao F. Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan. Front Cell Infect Microbial . 2020 jul; 10:404.
10. Gupta A, Madhavan MV, Sehga, K. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26: 1017–32 .
11. Deleers M, Breiman A, Daubie V, Maggetto C, Barreau I, Besse T, et al. Covid-19 and blood groups: ABO antibody levels may also matter. Int. J. Infect. Dis. 2020; 104: 242- 9.
12. Sebastian Kamps B, Hoffmann C. COVID Reference [Internet]. Hamburg: Steinhäuser Verlag; 2021. [ citado 5 /4/2022]. Disponible en: https://amedeo.com/CovidReference06.pdf
13. Government of Canada. Coronavirus disease (COVID-19). COVID-19 signs, symptoms and severity of disease: A clinician guide. [Internet]. Canadad: Government of Canada; 2021. [citado 28/08/2021]. Disponible en: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html
14. National Institutes of Health. COVID-19 Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection [Internet].Estados Unidos: NIH; 2021. [citado 30/08/2021]. Disponible en: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
15. Juventud Rebelde. La herencia roja. Sección Opinión. Juventud Rebelde. [Internet] 1 /08/2009. [citado 5/04/2022]. Disponible en: http://www.juventudrebelde.cu/cuba/2009-08-01/la-herencia-roja
16. Ahmet Nalbant, Ayhan Aydın, Selçuk Yaylacı, Tezcan Kaya, Charlotte Lynn Wermeulen, Hakan Cinemre. Association of ABO blood group and age with COVID-19 positive test. Rev Assoc Med Bras. 2021; 67(Suppl 1):46-50.
17. Dzik S, Eliason K, Morris EB, Kaufman RM, North CM. COVID-19 and ABO blood groups. Transfusion 2020; 60(8):1883-4.
18. Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Brit J Haematol. 2020; 190(1): 24-7.
19. Silva Filho JC, Farias de Melo CG, Lima de Oliveira J. The influence of ABO blood groups on COVID-19 susceptibility and severity: a molecular hypothesis based on carbohydrate-carbohydrate interactions. Med Hypotheses. 2020; 144:110155.
20. Gérard C, Maggipinto G, Minon JM. COVID-19 and ABO blood group: another viewpoint. Br J Haematol 2020; 190(2): e93-e4.

Downloads
Published
How to Cite
Issue
Section
License
Avisos de derechos de autor propuestos por Creative Commons
1. Política propuesta para revistas que ofrecen acceso abierto
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).